INVIVO THERAPEUTICS HLDGS CO's ticker is NVIV and the CUSIP is 46186M209. A total of 63 filers reported holding INVIVO THERAPEUTICS HLDGS CO in Q2 2016. The put-call ratio across all filers is 0.32 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2018 | $3,000 | 0.0% | 4,968 | 0.0% | 0.00% | – |
| Q1 2018 | $3,000 | -25.0% | 4,968 | 0.0% | 0.00% | – |
| Q4 2017 | $4,000 | -42.9% | 4,968 | 0.0% | 0.00% | – |
| Q3 2017 | $7,000 | -74.1% | 4,968 | -55.1% | 0.00% | – |
| Q2 2017 | $27,000 | -18.2% | 11,056 | +40.9% | 0.00% | – |
| Q1 2017 | $33,000 | +17.9% | 7,848 | +27.7% | 0.00% | – |
| Q4 2016 | $28,000 | +3.7% | 6,148 | +63.2% | 0.00% | – |
| Q3 2016 | $27,000 | +8.0% | 3,768 | 0.0% | 0.00% | – |
| Q2 2016 | $25,000 | +31.6% | 3,768 | 0.0% | 0.00% | – |
| Q1 2016 | $19,000 | -45.7% | 3,768 | -0.7% | 0.00% | -100.0% |
| Q4 2015 | $35,000 | -2.8% | 3,793 | 0.0% | 0.00% | 0.0% |
| Q3 2015 | $36,000 | -23.4% | 3,793 | +10.2% | 0.00% | 0.0% |
| Q2 2015 | $47,000 | – | 3,443 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| IMS Capital Management | 324,148 | $1,874,000 | 2.19% |
| SABBY MANAGEMENT, LLC | 580,343 | $3,354,000 | 0.18% |
| WELCH & FORBES LLC | 979,554 | $5,661,000 | 0.17% |
| Hayek Kallen Investment Management | 12,015 | $69,000 | 0.05% |
| Indiana Trust & Investment Management CO | 13,250 | $77,000 | 0.04% |
| BOSTON FINANCIAL MANGEMENT LLC | 74,175 | $429,000 | 0.04% |
| HYMAN CHARLES D | 32,100 | $186,000 | 0.03% |
| Baker Brothers Advisors | 400,000 | $2,312,000 | 0.02% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 90,650 | $524,000 | 0.01% |
| Edge Wealth Management LLC | 3,000 | $17,000 | 0.01% |